9. De Novo Autoimmune Hepatitis After Liver Transplantation In Children. Review

Authors

  • N.Zh. Yerimova JSC “National Scientific Center of surgery named after A.N.Syzganov”, Almaty, Kazakhstan
  • A.G. Akhbetova JSC “National Scientific Center of surgery named after A.N.Syzganov”, Almaty, Kazakhstan

Downloads

Abstract

De novo autoimmune hepatitis (AIH) is a clinical disease similar to AIH that develops in liver transplant recipients with diseases other than AIH. Timely recognition of this disease makes it possible to avoid graft rejection and liver re-transplan-tation (LT), liver fibrosis, and can ensure a long life expectancy, given the effectiveness of more active immunosuppression with the use of corticosteroids and azathioprine, as in the treatment of idiopathic AIH. The de novo prefix was added to distinguish this condition from primary autoimmune hepatitis prior to transplant, but the diagnostic algorithm adopted generally accepted diagnostic criteria for autoimmune hepatitis. In fact, de novo autoimmune hepatitis is characterized by typical necroinflammation of the liver, rich in plasma cells, increased serum gammaglobulin levels, and the appearance of inorganic specific autoantibodies. However, the general signs of autoimmune hepatitis de novo, apparently, cannot be associated with an unambiguous pathophysiological pathway, since they can develop in patients undergoing liver trans-plantation due to different etiologies. The literature review presents such aspects as the prevalence of this case, the influence of the HLA phenotype on the manifestation and outcome of the disease, diagnosis and treatment..

Objective. To conduct a literary review of scientific publications on the development of De novo Autoimmune hepatitis after liver transplantation in children..

Materials and methods. The authors selected scientific bases for the search such as: Web of science, Cyberleninka, UpToDate, Pubmed and Cochrane, Google Scholar..

Results. A meta-analysis of scientific articles in English and Russian was carried out for the selected keywords. The causes of development were not infectious or surgical complications. Liver biopsy revealed histological changes typical of acute or chronic ovulation. High levels of transaminases, hypergammaglobulinemia, positivity to autoantibodies – ANA, AMA, SMA, anti-LKM-1. De novo AIH patients did not respond to conventional anti-rejection therapy, but responded only to classical AIH therapy.

Keywords

schoolchildren, valvular regurgitations, prevalence https://

References

  1. Czaja A. Diagnosis Pathogenesis and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012 Sep;57(9):2248-66
  2. Zhang Y, Wang B, Wang T. De novo autoimmune hep-atitis with centrilobular necrosis following liver trans-plantation for primary biliary cirrhosis: a case report. Transplant Proc. 2010 Nov;42(9):3854-7
  3. Richter A, Grabhorn E, Helmke K, et al. Clini-cal relevance of autoantibodies after pediatric liver transplantation. Clin Transplant. 2007 May-Jun;21(3):427-32
  4. Cho JM, Kim KM, Oh SH, et al. De novo autoimmune hepatitis in Korean children after liver transplanta-tion: a single institution’s experience. Transplant Proc. 2011 JulAug;43(6):2394-6
  5. Damoiseaux, J.G., van Breda Vriesman, P.J. Cyclo-sporin Ainduced autoimmunity: the result of defec-tive de novo T-cell development. Folia Biol (Praha). 1998;(44):19
  6. Salcedo M, Rofriguez-Mahou M, Rodriguez-Sainz C, et al. Risk factors for developing de novo autoim-mune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl. 2009 May;15(5):530- 9
  7. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver bi-opsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006 Aug;44(2):489-501
  8. Miyagawa-Hayashino A., Haga H., Egawa H., Hayash-ino Y., Sakurai T., Minamiguchi S., Tanaka K., Manabe T. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Trans-plantation. 2004;78(1):128–35. PMID: 15257051
  9. Venick R.S., McDiarmid S.V., Farmer D.G., Gorn-bein J., Martin M.G., Vargas J.H., Ament M.E., Busuttil R.W. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007;7(4):955– 63. DOI:10.1111/j.1600-6143.2006.01717.x
  10. Pongpaibul A., Venick R.S., McDiarmid S.V., Lass-man C.R. Histopathology of de novo autoimmune hepatitis. Liver Transpl. 2012;18(7):811–8. DOI:10.1002/lt.23422
  11. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34:464–470
  12. Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplan-tation. Hepatology 2002;35:349–356
  13. Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: Introduction of antibody-mediated rejec-tion. Am J Transplant 2016;16:2816–2835
  14. Adeyi O, Fischer SE, Guindi M. Liver allograft pathol-ogy: approach to interpretation of needle biopsies with clinicopathological correlation. J Clin Pathol 2010;63:47–74. TRANSPLANTATION IN CHILDREN. REVIEW
  15. Pongpaibul A, Venick RS, McDiarmid SV, Lassman CR. Histopathology of de novo autoimmune hepatitis. Liver Transpl 2012;18:811–818
  16. Sebagh M, Castillo-Rama M, Azoulay D, Coilly A, Delvart V, Allard MA, et al. Histologic findings predic-tive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults. Transplantation 2013;96:670–678
  17. Luis Ibanez-Samaniego,Magdalena Salcedo,Javier Vaquero,Rafael Bañares. De novo autoimmune hepa-titis after liver transplantation: A focus on glutathi-one S-transferase theta 1, 06 October 2016, doi. 10.1002/lt.24652
  18. Maria Grazia Clemente, Roberto Antonucci, , Lucia Cicotto, Antonella Meloni, Bruno Gridelli, Stefano De Virgiliis, 1 Michael P. Manns, and Pietro Vajro. Auto-antibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis. 2017 doi:10.1155/2017/3563278
  19. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813– 1824
  20. Carbone M, Neuberger JM. Autoimmune liver dis-ease, autoimmunity and liver transplantation. J Hep-atol 2014;60:210–223
  21. Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent au-toimmune hepatitis after orthotopic liver transplanta-tion. Liver Transpl 2001;7:302–310
  22. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Trans-plant 2005;5:1085–1089
  23. Montano-Loza AJ, Vargas-Vorackova F, Ma M, Bain VG, Burak K, Kumar T, et al. Incidence and risk fac-tors associated with de novo autoimmune hepatitis after liver transplantation. Liver Int 2012;32:1426– 1433
  24. Puius YA, Dove LM, Brust DG, Shah DP, Lefkowitch JH. Three cases of autoimmune hepatitis in HIV-infected pa-tients. J Clin Gastroenterol 2008;42:425–429
  25. Wan DW, Marks K, Yantiss RK, Talal AH. Auto-immune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDS 2009;23:407–413

Published

2021-12-17

Issue

No. 4 (2021)

Section

Статьи